Jichuan Pharmaceutical: The registration application for Chai Ge Febrile Oral Liquid for Fever Relief has been accepted.

Jichuan Pharmaceutical announced that its wholly-owned subsidiary Jichuan Limited has received the "Acceptance Notice" issued by the National Medical Products Administration for the application for market approval of "Chai Ge Fever-reducing Oral Liquid". This medicine falls under the category 1.1 of traditional Chinese medicine, mainly used for symptoms such as fever and headache caused by wind-heat type common cold. As of now, the project has accumulated an investment of 59.1456 million RMB. According to publicly available information, there are currently no drugs in China with the same prescription as this product that have been marketed or applied for registration. The acceptance of this application marks the entry of domestic production of this product into the review stage, indicating future market development potential.